Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.82 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24428298 | 0.91 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL22853939 | 0.91 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL16487370 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL30267787 | 0.90 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL18644740 | 0.90 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL20983641 | 0.90 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL29381852 | 0.90 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL15703349 | 0.89 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20152981 | 0.89 | TLR7 (0.89) | TLR7TLR8 | |
| SCHEMBL20767365 | 0.89 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023208-A1 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2021-01-28 | — | — | US | disclosed |
| WO-2020252015-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10799580-B2 | Expression vector delivery system and use thereof for inducing an immune response | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-13 | — | — | US | disclosed |
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190151462-A1 | CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-05-23 | — | — | US | disclosed |
| US-10208037-B2 | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds | THE UNIVERSITY OF KANSAS (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180134701-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | THE UNIVERSITY OF KANSAS | 2018-05-17 | — | — | US | disclosed |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | UNIV YALE (US) | 2017-03-30 | — | — | US | disclosed |
| WO-2017044803-A1 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170029421-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | UNIV KANSAS (US) | 2017-02-02 | — | — | US | disclosed |
| US-9556167-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2013166110-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR_ARMS) | YALE UNIVERSITY (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20120294885-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | THE UNIVERSITY OF KANSAS (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | TLR7, TLR8, TLR9 | TLR7 1/4885TLR8 2/4885 |
| US-20190151462-A1 | CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF | TLR7, TLR8, TLR9 | TLR7 1/4885TLR8 2/4885 |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | TLR3, TLR4, TLR1 | TLR7 9/4885TLR8 8/4885 |
| US-10799580-B2 | Expression vector delivery system and use thereof for inducing an immune response | CD69, CD14, CD4 | TLR7 27/4885TLR8 15/4885 |
| US-20180134701-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-20170029421-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-20120294885-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-10208037-B2 | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-20210023208-A1 | EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE | CD69, CD14, CD4 | TLR7 27/4885TLR8 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.